REG - ConvaTec Group PLC - 2018 Annual Report & Accounts

ConvaTecAnnouncement

27/02/2019 12:40

RNS Number : 3078R
ConvaTec Group PLC
27 February 2019
 


 
2018 Annual Report & Accounts
 
 
READING, UNITED KINGDOM (27 February 2019) - ConvaTec Group Plc ("ConvaTec" or the "Group"), a leading global medical products and technologies company, has today published on the Group's website its Annual Report & Accounts for the year ended 31 December 2018 (the "Annual Report").  The Annual Report is available at www.convatecgroup.com.
 
In compliance with Listing Rule 9.6.1, a copy of the Annual Report will also shortly be submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.co.uk/uk/NSM.
 
The Annual Report, together with notice of the Group's Annual General Meeting to be held on 9 May 2019, will be sent to shareholders in due course, at which point a further announcement will be made.
 
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com.
 
Enquiries
 
Media
Bobby Leach, VP Group Corporate Affairs, ConvaTec                     +44 (0)7770 842 226
Finsbury                                                                                            +44 (0)207 251 3801
 
Analysts and Investors
John Crosse, VP Investor Relations, ConvaTec                             +44 (0)7500 141 435
Mark Reynolds, Director Investor Relations, ConvaTec                 +44 (0)7551 036 625
investorrelations@convatec.com
 
 
 
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
# # #
END




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACSFMGZZZNMGLZM